Analysis of the urine proteome in patients with pancreatic ductal adenocarcinoma.

Pancreatic ductal adenocarcinoma (PDAC) accounts for over 213 000 deaths worldwide each year, largely due to late diagnosis. One of the risk factors for the development of PDAC is chronic pancreatitis (CP); the intense desmoplastic reaction makes differentiation between the two conditions extremely difficult. In order to identify biomarkers for noninvasive diagnosis, we performed 2-D DIGE analysis of urine samples from healthy individuals and patients with PDAC and CP. Despite considerable intersample heterogeneity, a total of 127 statistically valid (p<0.05), differentially expressed protein spots were detected, 101 of which were identified using MALDI-TOF MS. A number of these, including annexin A2, gelsolin and CD59 have already been associated with PDAC, however, their validation using immunoblotting proved challenging. This is probably due to extensive PTMs and processing thus indicating the need for raising specific antibodies for urinary proteins. Despite this, our study clearly demonstrates that urine is a valid source of noninvasive biomarkers in patients with pancreatic diseases.
AuthorsMark E Weeks, Deepak Hariharan, Ljiljana Petronijevic, Tomasz P Radon, Hannah J Whiteman, Hemant M Kocher, John F Timms, Nicholas R Lemoine, Tatjana Crnogorac-Jurcevic
JournalProteomics. Clinical applications (Proteomics Clin Appl) Vol. 2 Issue 7-8 Pg. 1047-57 (Jul 2008) ISSN: 1862-8346 [Print] Germany
PMID21136905 (Publication Type: Journal Article)
CopyrightCopyright © 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: